Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate
Abstract Introduction The objective of this analysis was to assess disease activity metrics using a variety of disease outcome measures following methotrexate (MTX) withdrawal in ORAL Shift, a phase 3b/4 study of tofacitinib with/without MTX, in patients with rheumatoid arthritis (RA) achieving Clin...
Main Authors: | Roy Fleischmann, Boulos Haraoui, Maya H. Buch, David Gold, Gosford Sawyerr, Harry Shi, Annette Diehl, Kristen Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2022-12-01
|
Series: | Rheumatology and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s40744-022-00511-3 |
Similar Items
-
Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy
by: Tsutomu Takeuchi, et al.
Published: (2021-08-01) -
Methotrexate in Treatment of Rheumatoid Arthritis
by: Wiewiόrowski Maciej, et al.
Published: (1999-08-01) -
Methotrexate intolerance in Rheumatoid Arthritis
by: Harjit Singh Nalwa, et al.
Published: (2023-03-01) -
Safety and efficacy of Methotrexate Monotherapy Vs Methotrexate Plus Leflunomide Combination Therapy in Early Active Rheumatoid Arthritis Patients
by: Mariane S. Boshra, et al.
Published: (2016-03-01) -
Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift)
by: Boulos Haraoui, et al.
Published: (2021-08-01)